Terms: = Endocrine gland cancer AND H3F3B, H3_3A, 3021, ENSG00000132475, P84243, H3_3B, MGC87783, MGC87782, H3F3
7 results:
1. Co-occurrence of mutations in
Mellid S; Gil E; Letón R; Caleiras E; Honrado E; Richter S; Palacios N; Lahera M; Galofré JC; López-Fernández A; Calatayud M; Herrera-Martínez AD; Galvez MA; Matias-Guiu X; Balbín M; Korpershoek E; Lim ES; Maletta F; Lider S; Fliedner SMJ; Bechmann N; Eisenhofer G; Canu L; Rapizzi E; Bancos I; Robledo M; Cascón A
Front Endocrinol (Lausanne); 2022; 13():1070074. PubMed ID: 36760809
[TBL] [Abstract] [Full Text] [Related]
2. High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
Bick U; Engel C; Krug B; Heindel W; Fallenberg EM; Rhiem K; Maintz D; Golatta M; Speiser D; Rjosk-Dendorfer D; Lämmer-Skarke I; Dietzel F; Schäfer KWF; Leinert E; Weigel S; Sauer S; Pertschy S; Hofmockel T; Hagert-Winkler A; Kast K; Quante A; Meindl A; Kiechle M; Loeffler M; Schmutzler RK;
Breast Cancer Res Treat; 2019 May; 175(1):217-228. PubMed ID: 30725383
[TBL] [Abstract] [Full Text] [Related]
3. Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian cancer Cell Lines.
Papp E; Hallberg D; Konecny GE; Bruhm DC; Adleff V; Noë M; Kagiampakis I; Palsgrove D; Conklin D; Kinose Y; White JR; Press MF; Drapkin R; Easwaran H; Baylin SB; Slamon D; Velculescu VE; Scharpf RB
Cell Rep; 2018 Nov; 25(9):2617-2633. PubMed ID: 30485824
[TBL] [Abstract] [Full Text] [Related]
4. An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021).
Lee SW; Kim YM; Cho CH; Kim YT; Kim SM; Hur SY; Kim JH; Kim BG; Kim SC; Ryu HS; Kang SB
Cancer Res Treat; 2018 Jan; 50(1):195-203. PubMed ID: 28324920
[TBL] [Abstract] [Full Text] [Related]
5. Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients.
Fontana A; Copetti M; Di Gangi IM; Mazza T; Tavano F; Gioffreda D; Mattivi F; Andriulli A; Vrhovsek U; Pazienza V
Oncotarget; 2016 Feb; 7(8):8968-78. PubMed ID: 26840268
[TBL] [Abstract] [Full Text] [Related]
6. Involvement of serum retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers in Hungary.
Mózsik G; Rumi G; Dömötör A; Figler M; Gasztonyi B; Papp E; Pár A; Pár G; Belágyi J; Matus Z; Melegh B
World J Gastroenterol; 2005 Dec; 11(48):7646-50. PubMed ID: 16437692
[TBL] [Abstract] [Full Text] [Related]
7. Identification of novel variant, 1484delG in the 3'UTR of h3f3b, a member of the histone 3B replacement family, in ovarian tumors.
Presneau N; Shen Z; Provencher D; Mes-Masson AM; Tonin PN
Int J Oncol; 2005 Jun; 26(6):1621-7. PubMed ID: 15870878
[TBL] [Abstract] [Full Text] [Related]
